术前立体定向放射外科联合手术切除治疗1-4个脑转移瘤的疗效及放射生物学相关性分析:II期试验研究方案
这是一项前瞻性单臂II期试验的研究方案,计划纳入最多4个脑转移灶且至少有一个可切除病灶的患者,所有病灶接受立体定向放射外科治疗,症状性病灶在SRS后1-4天内切除,主要评估6个月局部控制率,并进行放射生物学分子研究。
要点
- 术前SRS后1-4天内切除症状性病灶,评估6个月局部控制。
- 同时评估脑内无进展生存、远处脑内失败、软脑膜播散率、放射性坏死和总生存。
- 将进行放射生物学分子研究,评估辐射剂量对肿瘤组织及临床结局的影响。
核心结论
- 研究旨在评估术前SRS后手术切除对1-4个脑转移瘤患者的6个月局部控制效果。
- 研究者预期术前SRS至肉眼肿瘤再手术切除可改善局部控制并减少软脑膜失败。
研究设计与样本
- 前瞻性、单臂、II期试验,招募最多4个脑转移灶且至少有一个可切除病灶的患者。
- 所有病灶接受SRS,症状性病灶在SRS后1-4天内切除。
- 监测6个月局部控制、脑内无进展生存、远处脑内失败、软脑膜播散率、放射性坏死和总生存。
关键数值与推荐
- 术前SRS后1-4天内切除症状性病灶。
- 主要评估指标为6个月局部控制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic radiosurgery (SRS) has emerged as a common adjuvant modality used with surgery for resectable brain metastases (BMs). However, the optimal sequence of the multi-modality therapy has not been established. The goal of the study is to evaluate 6-month local control utilizing pre-operative SRS followed by surgical resection for patients with 1-4 brain metastases. METHODS: This prospective, single arm, phase II trial will recruit patients with up to 4 brain metastases and at least one resectable lesion. All lesions will be treated with SRS and symptomatic lesions will be resected within 1-4 days after SRS. Patients will be monitored for 6-month local control, in-brain progression free survival, distant in-brain failure, rate of leptomeningeal spread, radiation necrosis and overall survival. Additionally, we will also perform correlative radiobiological molecular studies to assess the effect of radiation dosing on the tumor tissue and clinical outcomes. We expect that pre-operative SRS to the gross tumor prior to surgical resection will improve local control and decrease leptomeningeal failure. DISCUSSION: Our study is the second prospective trial to investigate the efficacy of pre-operative SRS in the treatment of multiple BMs. In addition, the correlative molecular studies will be the first to investigate early response of BMs at a cellular and genetic level in response to radiation doses and potentially provide molecular prognostic markers for local control and overall survival. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03398694 (registration date: January 12, 2018).
引用
- Huff WX, Agrawal N, Shapiro S, et al. Efficacy of pre-operative stereotactic radiosurgery followed by surgical resection and correlative radiobiological analysis for patients with 1-4 brain metastases: study protocol for a phase II trial. Radiat Oncol. 2018. PMID: 30572923. doi:10.1186/s13014-018-1178-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。